Literature DB >> 6989766

Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma.

R T Morgan, L K Woods, G E Moore, L A Quinn, L McGavran, S G Gordon.   

Abstract

A continuous human cell line, COLO 357, with exceptional characteristics was derived from a metastasis of a pancreatic adenocarcinoma. COLO 357 grew as an adhering monolayer with a cell doubling time of 21 h and grew with 10% clonal efficiency in soft agar. COLO 357 cells had numerous lamellar inclusions. The cells elaborated the pancreatic enzymes trypsin, elastase and chymotrypsin. COLO 357 also secreted appreciable amounts of carcinoembryonic antigen and human chorionic gonadotropin. COLO 357 had a chromosome mode of 53 with 20 identifiable Giemsa-banded marker chromosomes. Nine nucleolar organizing regions were found by silver-stained metaphase preparations. COLO 357 has been "fingerprinted" for seven allelic isozymes. This cell line has been maintained in active culture for over 2 years, is preserved in a cell bank, and is available to other investigators.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989766     DOI: 10.1002/ijc.2910250507

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

1.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines.

Authors:  Yogesh Kumar; Sybille Mazurek; Shiyu Yang; Klaus Failing; Marc Winslet; Barry Fuller; Brian R Davidson
Journal:  Tumour Biol       Date:  2010-02-24

3.  Phosphorylation of CK1delta: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo.

Authors:  Georgios Giamas; Heidrun Hirner; Levani Shoshiashvili; Arnhild Grothey; Susanne Gessert; Michael Kühl; Doris Henne-Bruns; Constantinos E Vorgias; Uwe Knippschild
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

4.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

5.  Culture of human main pancreatic duct epithelial cells.

Authors:  D Oda; C E Savard; T D Nguyen; E R Swenson; S P Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-03       Impact factor: 2.416

6.  Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.

Authors:  Lars Boenicke; Kang Chu; Regina Pauls; Claudia Tams; Marie-Luise Kruse; Roland Kurdow; Bodo Schniewind; Arnd Böhle; Bernd Kremer; Holger Kalthoff
Journal:  J Mol Med (Berl)       Date:  2003-03-18       Impact factor: 4.599

7.  Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP.

Authors:  Honoré Ngora; Uwe M Galli; Kaoru Miyazaki; Margot Zöller
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

8.  Runx2 expression: A mesenchymal stem marker for cancer.

Authors:  Maria Teresa Valenti; Paola Serafini; Giulio Innamorati; Anna Gili; Samuele Cheri; Claudio Bassi; Luca Dalle Carbonare
Journal:  Oncol Lett       Date:  2016-09-23       Impact factor: 2.967

9.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Xiangdong Le; Chen Huang; Zhiliang Jia; Jiujie Cui; Suyun Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.